Нейролайф Китай
FRDA

Treatment of FRDA in

Friedreich's ataxia rehabilitation at NeuroLife Huizhou focuses on coordination training, balance, and maintenance of functional capabilities in this progressive disease. We work with motor disturbances (ataxia, dysarthria), associated scoliosis and foot deformities, and gentle TCM approaches to support cardiac function — cardiomyopathy remains the main cause of complications in FRDA.

Замедление прогрессирования
improvement
patients
2 courses per year + home program
course
About the condition

What is Friedreich's Ataxia?

Friedreich's ataxia (FRDA) is the most common hereditary ataxia, while still a rare disease (1 in 50000). ICD-10 code G11.1. The underlying cause is an autosomal recessive mutation in the FXN gene on chromosome 9q21.11, encoding the mitochondrial protein frataxin. Frataxin deficiency disrupts iron-sulfur metabolism in mitochondria and produces progressive degeneration of the posterior spinal columns, dentate nuclei of the cerebellum, peripheral nerves, and cardiac muscle. Clinically onset is typically at ages 5–15 (though late-onset forms exist) with progressive ataxia — impaired coordination, staggering gait, dysarthria, loss of deep sensation. In parallel — scoliosis (in 80%+ of cases), foot deformities (pes cavus in 50–80%), cardiomyopathy (40%), and diabetes (10%) develop. Progression is slow but inexorable — the mean age of losing independent ambulation is about 25 years from onset. There is no disease-stopping therapy yet, although in 2023 the FDA approved the first drug (omaveloxolone / Skyclarys) for FRDA — it slows progression. On the horizon are gene and cell therapies. However rehabilitation already today significantly affects quality of life, extends functional capabilities, and preserves independence. Our Huizhou program: coordination training (exercises for movement accuracy, smoothness, and timing — critically important in ataxia), balance therapy (stabilometric platforms, exercises on unstable surfaces, proprioceptive stimulation), occupational therapy with adaptive device selection (special walkers, stabilizers, weighted utensils), specialized therapeutic exercise to preserve muscle mass and joint mobility, physiotherapy, massage. For scoliosis — a custom orthosis + posture work; for pes cavus — biomechanical insoles. A special section is gentle TCM approaches to support the heart. Hypertrophic cardiomyopathy develops in 40% of patients, and any myocardial support is valuable. Acupuncture at specific cardiac points (with mandatory cardiologist coordination), gentle lymphatic drainage massage, individual herbal blends for general state. In parallel — coordination with the pediatric cardiologist (annual echocardiography, ECG monitoring) and endocrinologist (diabetes risk).

Causes

Autosomal recessive mutation in the FXN gene on chromosome 9q21.11. In 95% of patients — GAA repeat expansion in the first FXN intron (normal — up to 33 repeats, FRDA — 66 to 1700+ repeats on both alleles). This reduces expression of the mitochondrial protein frataxin, disrupts iron-sulfur metabolism, and gradually causes death of neurons and cardiomyocytes. Carrier rate is about 1 in 60–100 in populations of European descent.

Symptoms

Progressive ataxia — impaired coordination (of arms, legs, trunk), staggering wide-based gait, dysmetria (overshoot in goal-directed movements). Dysarthria (slurred speech). Loss of deep sensation (vibratory, joint-position). Scoliosis. Pes cavus. Reduced or absent tendon reflexes. Gradually — cardiomyopathy (dyspnea, arrhythmias), diabetes, vision and hearing impairments.

Diagnostics

The gold standard is FXN genetic analysis (GAA repeat counting). Additional — brain and spinal cord MRI (cerebellar and posterior spinal column atrophy), EMG (characteristic axonal pattern), nerve conduction, echocardiography and ECG (mandatory annually for cardiomyopathy detection), function assessment by the SARA (Scale for the Assessment and Rating of Ataxia) or FARS scale, lab work — fasting glucose and HbA1c for diabetes screening.

Prognosis

The disease is progressive. The mean age of losing independent ambulation is about 25 years from onset. The main cause of mortality is cardiomyopathy and related arrhythmias. Modern therapy (omaveloxolone since 2023) slows progression, and regular rehabilitation significantly affects functional independence and quality of life. Cardiologist coordination is critical — timely management of cardiac complications meaningfully impacts life expectancy.

Our approach

How we treat

01

Diagnostics

Comprehensive examination and patient assessment by an international team of specialists

02

Treatment plan

Development of an individual rehabilitation program considering diagnosis specifics

03

Therapy

Intensive course of procedures: physical therapy, massage, physiotherapy, acupuncture and other methods

04

Results

Progress evaluation, home recommendations and maintenance therapy plan

FAQ

Questions about treatment of Friedreich's Ataxia

Book a free consultation

A doctor will review your documents and provide recommendations within 30 minutes.

Leave a request

By clicking the button, you agree to the privacy policy

We use cookies and analytics to improve the website experience. Privacy Policy